Orion Oyj B
Research Orion Oyj B (ORNBV) on Bullrun: valuation model: 22.4% undervalued, market cap EUR 11.24B, P/E 19.1, dividend yield 2.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerORNBV
- ExchangeHE
- CountryFinland
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyEUR
- Valuation signal22.4% undervalued
- Market capEUR 11.24B
- P/E19.1
- Dividend yield2.2%
- Financial periodQ2 2026
- RevenueEUR 521.60M
- Net incomeEUR 140.20M
- Free cash flowEUR 255.90M
- Gross margin65.2%
Valuation Snapshot
Bullrun's latest valuation model marks Orion Oyj B as 22.4% undervalued; latest market cap is EUR 11.24B; P/E is 19.1; dividend yield is 2.2%.
Peer valuation comparison
Latest P/E is 19.09x versus a Healthcare sector median of 24.46x (22.0% below).
Latest dividend yield is 2.15% versus a Healthcare sector median of 2.11%.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.89B | EUR 500.30M | n/a | 64.2% | n/a | EUR 160.90M | EUR 305.30M | EUR 1.28B |
| FY2024 | EUR 1.54B | EUR 330.00M | n/a | 61.4% | n/a | EUR 205.60M | EUR 327.30M | EUR 1.01B |
| FY2023 | EUR 1.19B | EUR 216.70M | n/a | 55.3% | n/a | EUR 106.70M | n/a | n/a |
| FY2022 | EUR 1.34B | EUR 349.60M | n/a | 63.5% | n/a | EUR 332.60M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 11.24B | 19.1 | 2.3% | 1.8 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.8 EUR, yield 2.2%.
About Orion Oyj B
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Orion Oyj B overvalued or undervalued?
Bullrun's valuation model currently marks Orion Oyj B as 22.4% undervalued.
What is Orion Oyj B's market cap?
Orion Oyj B's market capitalization is EUR 11.24B.
What is Orion Oyj B's P/E ratio?
Orion Oyj B's price-to-earnings (P/E) ratio is 19.1.
Does Orion Oyj B pay a dividend?
Orion Oyj B has a dividend yield of 2.2%.
What does Orion Oyj B do?
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.